[Synthetic proteins with antiviral properties of alpha-interferons]. 2003

R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, GSP Moscow, 117997 Russia. rita@nmr.ru

Consensus sequence 30-36 LKDRHDF of human alpha-interferons is inserted into the C- and N-terminal sequences of the artificial protein albeferon using genetic engineering methods in order to obtain artificial proteins with antiviral activity. Albeferon, obtained by Dolgikh et al. (Protein Eng., 1996, vol. 9, pp. 195-201), already contains the IFN-alpha 2 130-137 fragment and possesses antiproliferative activity comparable with that of IFN-alpha 2. According to CD spectroscopy, both proteins have regular secondary structures similar to that of the precursor protein. They exhibit antiviral activities, and the activity of one of them is comparable with that of IFN-alpha 2. At the same time, their cytotoxic properties are displayed only at relatively high concentrations, which substantially exceed the minimal antiviral concentrations.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
September 1971, Die Naturwissenschaften,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
February 1988, Journal of interferon research,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
February 2015, BMC veterinary research,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
January 1985, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
February 1995, Annals of medicine,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
December 1998, Journal of reproductive immunology,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
October 2001, Clinical microbiology reviews,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
September 1977, Bacteriological reviews,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
May 2001, Current protocols in immunology,
R V Chertkova, and Z Kh Abdullaev, and D A Dolgikh, and V P Zav'ialov, and M P Kirpichnikov
June 1998, Cancer research,
Copied contents to your clipboard!